FrEBT
Improving diagnostics of respiratory diseases and boosting the COMAC MEDICAL Ltd. competitiveness and growth by validation of fractional EBT biomarker through new method of measurement and device
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0FrEBT project word cloud
Explore the words cloud of the FrEBT project. It provides you a very rough idea of what is the project "FrEBT" about.
Project "FrEBT" data sheet
The following table provides information about the project.
| Coordinator |
COMAC MEDICAL LTD
Organization address contact info |
| Coordinator Country | Bulgaria [BG] |
| Project website | http://comac-medical.com/ |
| Total cost | 71˙429 € |
| EC max contribution | 50˙000 € (70%) |
| Programme |
1. H2020-EU.3.1.3. (Treating and managing disease) |
| Code Call | H2020-SMEINST-1-2015 |
| Funding Scheme | SME-1 |
| Starting year | 2015 |
| Duration (year-month-day) | from 2015-09-01 to 2015-10-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | COMAC MEDICAL LTD | BG (SOFIA) | coordinator | 50˙000.00 |
Map
Project objective
The innovation project objectives are to: 1/prove through a feasibility study the potential to validate the Fractional Exhaled Breath Temperature, via new viable and disruptive technological device, as a diagnostic, prognostic and monitoring biomarker for inflammatory and obstructive pulmonary diseases; 2/enhance the competitiveness and profitability of the full- service clinical research organization COMAC MEDICAL Ltd., operating via own network of partners in 14 countries from 3 European regions with population of over 118 mln. The commercial potential of the innovative solution is that it is a best alternative of the existing methods on market, saving great number of diagnosis‘ stages without any potential risk for the patients, being more precise, user friendly, non-invasive, less painful, faster, cost effective, covering vulnerable groups of children, young and elderly people, saving lives, increasing workforce capabilities. It is a response to the EU wide and global challenges related to the respiratory diseases causing high level of morbidity and mortality–at about 1 million deaths annually in the European Region; 2/3 of them in EU28, with total cost there of € 380 bln. The expected SME growth is 20%, leading to specialisation in Pulmonology and Oncology and filling a market niche. The SME will launch into new markets in Europe and Asia, increasing its market share in clinical trials - 12-15% in Bulgaria;10% in Europe and 2-5% worldwide. The outcome of the Phase1 project is a feasibility study, assessing the socio-economic, commercial, technical aspects of the innovation, based on 6 steps of activities on: the Description of the innovative solution;Market/Technical Feasibility;Financial/Economic Feasibility; Organizational/Managerial Feasibility;Risk assessment;IP Management. The targeted users are the patients through the healthcare systems and the doctors, specialists in respiratory diseases and lung cancer as well as the GPs.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FREBT" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "FREBT" are provided by the European Opendata Portal: CORDIS opendata.